Zhang, Gao

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersExtracellular vesicles in disease

Cited by 2,813

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,429

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 594

Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

Ma, X.-H., Piao, S.-F., Dey, S., Mcafee, Q., Karakousis, G., Villanueva, J., Hart, L. S., Levi, S., Hu, J., Zhang, G., et al. (2014) · Journal of Clinical Investigation

Melanoma and MAPK PathwaysAutophagy in Disease and Therapy

Cited by 457

Targeting TBK1 to overcome resistance to cancer immunotherapy

Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., et al. (2023) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 174

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., Wagner, C., Hristova, D., Zhang, J., Tian, T., et al. (2017) · Nature Communications

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 151

A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF -mutated Melanoma to MAPK Inhibitors

Aloia, A., Müllhaupt, D., Chabbert, C. D., Eberhart, T., Flückiger-Mangual, S., Vukolic, A., Eichhoff, O., Irmisch, A., Alexander, L. T., Scibona, E., et al. (2019) · Clinical Cancer Research

Melanoma and MAPK PathwaysCancer, Lipids, and Metabolism

Cited by 130

Melanoma‐derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature

Wang, T., Ge, Y., Xiao, M., Lopez‐Coral, A., Azuma, R., Somasundaram, R., Zhang, G., Wei, Z., Xu, X., Rauscher, F. J., et al. (2012) · Pigment Cell & Melanoma Research

Immune cells in cancerCancer, Stress, Anesthesia, and Immune Response

Cited by 69

Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells

Simpkins, F., Jang, K., Yoon, H., Hew, K. E., Kim, M., Azzam, D. J., Sun, J., Zhao, D., Ince, T. A., Liu, W., et al. (2018) · Clinical Cancer Research

Ovarian cancer diagnosis and treatmentCancer Cells and Metastasis

Cited by 67

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene

Melanoma and MAPK PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 66

miR‐200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment

Liu, S., Tetzlaff, M. T., Wang, T., Yang, R., Xie, L., Zhang, G., Krepler, C., Xiao, M., Beqiri, M., Xu, W., et al. (2015) · Pigment Cell & Melanoma Research

Melanoma and MAPK PathwaysMicroRNA in disease regulation

Cited by 54